Abstract
Orthoclone OKT3 has been marketed since 1986 for reversal of human kidney graft rejections.* Widely used for reversal of rejections and for rescue of steroid-resistant rejections, some groups have experimented with the use of OKT3 in other antirejection applications (Bristow et al., 1988; Cosimi et al., 1990). OKT3 is a murine monoclonal antibody directed to a component of the antigen receptor present on all mature, human T cells. The OKT designation derives from its origin (Ortho Pharmaceutical Corporation, lab of Patrick Aung) and its specificity (T cells). It has been given the generic name, Muromonab CD3. When OKT3 is administered to a person experiencing rejection, all circulating peripheral T cells disappear from circulation within 30 min of the first injection (Chatenoud et al., 1982; Norman et al., 1987). Mature T cells remain absent throughout the first 7–10 days of treatment, although T cells bearing other T cell surface markers reappear earlier. However, these cells typically lack the T cell receptor for antigen and are unable to respond to foreign antigens, making graft rejection impossible. Patients receive a course of treatment for 10–14 days and clinical signs of rejection reversal are usually present by the third to fifth day of treatment (Ortho Multicenter Transplant Study Group, 1985; Thistlethwaite et al., 1987). After the course of OKT3 therapy, the patient resumes his normal immunosuppressive regimen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aebersold, R. H., Leavitt, J., Saavedra, R. A., Hood, R. E., and Kent, S. B. H., 1987, N-terminal amino acid sequence analysis of proteins separated by one or two dimensional gel electrophoresis after in situ digestion on nitrocellulose, Proc. Natl. Acad. Sci. USA 84:6970–6974.
Amzel, L. M., and Poljak, R. J., 1979, Three-dimensional structure of immunoglobulins, Annu. Rev. Biochem. 48:961–997.
Bristow, M. R., Gilbert, E. M., O’Connell, J. B., Renlund, D. G., Watson, F. S., Hammond, E., Lee, R. G., and Menlove, R., 1988, OKT3 monoclonal antibody in heart transplantation, Am. J. Kidney Dis. 11:135–147.
Capasso, S., Mazzarella, L., Sica, F., and Zagari, A., 1989, Deamidation via cyclic imide in asparaginyl peptides, Pept. Res. 2:195–200.
Chang, T. W., Kung, P. C., Gingras, S. P., and Goldstein, G., 1981, Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc. Natl. Acad. Sci. USA 78:1805–1808.
Chatenoud, L., Baudrihaye, M., Kreis, H., Goldstein, G., Schlindler, J., and Bach, J. F., 1982, Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody, Eur. J. Immunol. 12:979–982.
Chazin, W. J., Kordel, J., Thulin, E., Hofmann, T., Drakenberg, T., and Forsen, S., 1989, Identification of an isoaspartyl linkage formed upon deamidation of bovine calbindin D9k and structural characterization by 2D 1H NMR, Biochemistry 28:8646–8653.
Cosimi, A. B., Jenkins, R. L., Rohrer, R. J., Delmonico, F. L., Hoffman, M., and Monaco, A. P., 1990, A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients, Arch. Surg. 125:781–784.
DiAugustine, R. P., Gibson, B. W., Aberth, W., Kelly, M., Ferrua, C. M., Tomooka, Y., Brown, C. F., and Walker, M., 1987, Evidence for isoaspartyl (deamidated) forms of mouse epidermal growth factor. Anal. Biochem. 165:420–429.
Edelman, G. M., 1971, Antibody structure and molecular immunology, Ann. N.Y. Acad. Sci. 190:5–25.
Imoto, T., and Rupley, J. A., 1973, Oxidation of lysozyme by iodine: Identification and properties of an oxindolyl ester intermediate; evidence for participation of glutamic acid 35 in catalysis, J. Mol Biol. 80:657–667.
Johnson, B. A., Shirokawa, J. M., Hancock, W. S., Spellman, M. W., Basa, L. J., and Aswad, D. W., 1989, Formation of isoaspartate at two distinct sites during in vitro aging of human growth hormone, J. Biol. Chem. 264:14262–14271.
Kossiakoff, A. A., 1988, Tertiary structure is a principal determinant to protein deamidation, Science 240:191–194.
Kung, P., Goldstein, G., Reinherz, E., and Schlossman, S., 1979, Monoclonal antibodies defining distinctive human T cell surface antigens, Science 206:347–349.
Manning, M. C., Patel, K., and Borchardt, R. T., 1989, Stability of protein pharmaceuticals, Pharm. Res. 6:903–918.
Matsudaira, P., 1987, Sequences from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes, J. Biol. Chem. 262:10035–10038.
Nisonoff, A., Hopper, J. E., and Spring, S. B., 1975, The Antibody Molecule, Academic Press, New York.
Norman, D. J., Shield, C. F., Barry, J., Hennell, K., Funnell, M. B., and Lemon, J., 1987, A U.S. clinical study of Orthoclone OKT3 in renal transplantation, Transplant. Proc. 19:21–27.
Ohta, T., and Nakai, T., 1978, The reaction of tryptophan with cystine during acid hydrolysis of proteins, Biochim. Biophys. Acta 533:440–445.
Ortho Multicenter Transplant Study Group, 1985, A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants, N. Engl. J. Med. 313:337–342.
Reinherz, E. L., Hussey, R. E., and Schlossman, S. F., 1980, A monoclonal antibody blocking human T cell function, Eur. J. Immunol. 10:758.
Savige, W. E., 1976, New oxidation and photo-oxidation products of tryptophan, Proc. Int. Wolltextil-Forschungskonf., 5th 1975 2:570–579.
Smith, K. G. G, Austyn, J. M., Hariri, G., Beverly, P. G L., and Morris, P. J., 1986, T cell activation by anti-T3 antibodies: Comparison of IgGl and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors, Eur. J. Immunol. 16:478–483.
Stephenson, R. G, and Clarke, S., 1989, Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins, J. Biol. Chem. 264:6164–6170.
Tax, W. J. M., Willems, H. W., Reekers, P. P. M., Capel, P. J. A., and Koene, R. A. P., 1983, Polymorphism in mitogenic effect of IgGl monoclonal antibodies against T3 antigen on human T cells, Nature 304:445–447.
Tax, W. J. M., Hermes, F. F. M., Willems, H. W., Capel, P. J. A., and Koene, R. A. P., 1984, Fc receptors for mouse IgGl on human monocytes: polymorphism and role in antibody-induced T cell proliferation, J. Immunol 133:1185–1189.
Thannhauser, T. W., Konishi, Y., and Scheraga, H. A., 1984, Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins, Anal Biochem. 138:181–188.
Thistlethwaite, J. R., Gaber, A. O., Haag, B. W., Aronson, A. J., Broelsch, G E., Stuart, J. K., and Stuart, F. P., 1987, OKT3 treatment of steroid-resistant renal allograft rejection, Transplantation 43:176–184.
VanWauwe, J. P., DeMay, J. R., and Goossens, J. G., 1980, OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J. Immunol 124:2708–2713.
Violand, B. N., Schlittler, M. R., Toren, P. G, and Siegel, N. R., 1990, Formation of isoaspartate 99 in bovine and porcine somatotropins, J. Prot. Chem. 9:109–117.
Yuksel, K. U., and Gracy, R. W., 1986, In vitro deamidation of human triosephos-phate isomerase, Arch. Biochem. Biophys. 248:452–459.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rao, P.E., Kroon, D.J. (1993). Orthoclone OKT3. In: Wang, Y.J., Pearlman, R. (eds) Stability and Characterization of Protein and Peptide Drugs. Pharmaceutical Biotechnology, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1236-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1236-7_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1238-1
Online ISBN: 978-1-4899-1236-7
eBook Packages: Springer Book Archive